University of Cambridge > > The Inaugural Kate Pretty Lecture  > WHAT SCIENCE CAN DO: The Cambridge life science cluster at a pivot point

WHAT SCIENCE CAN DO: The Cambridge life science cluster at a pivot point

Add to your list(s) Download to your calendar using vCal

  • UserPascal Soriot, CEO of AstraZeneca
  • ClockThursday 08 March 2018, 17:30-19:15
  • HouseHomerton College.

If you have a question about this talk, please contact Rebekah-Miron Clayton.

Pascal Soriot, CEO of AstraZeneca, delivers the second annual Kate Pretty Lecture on ‘What Science Can Do: The Cambridge life science cluster at a pivot point’

The Kate Pretty Lecture Series honours Dr Kate Pretty CBE , Principal of Homerton College (1991-2013) and Pro-Vice-Chancellor of the University of Cambridge (2004-2010), responsible for international strategy, outreach, lifelong learning, and museums and libraries. An archaeologist, Dr Pretty served as President of the Council for British Archaeology from 2008-2013. Dr Pretty’s time as Principal saw the College mark 100 years in Cambridge, widen its expertise across subject disciplines, and eventually become a full College of the University of Cambridge.

The first lecture in this new series was entitled ‘The Cambridge of Tomorrow’, and was delivered by the then Vice-Chancellor of the University of Cambridge, Professor Sir Leszek Borysiewicz FRS . This lecture took place on February 17 and over 200 guests attended, both from the University of Cambridge and the wider community. This year, we are privileged to welcome Pascal Soriot, CEO of biopharmaceutical company AstraZeneca. AstraZeneca recently relocated their headquarters to Cambridge, and we look forward to working with them more closely in the future.

As CEO of AstraZeneca, Pascal brings a passion for science and medicine as well as significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organisation. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC , Paris. In 2012 he became Executive Director and Chief Executive Officer of AstraZeneca.

Attendance is free but booking is required:

This talk is part of the The Inaugural Kate Pretty Lecture series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity